EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic insights into edoxaban’s nonlinear pharmacokinetics and quinidine interaction via P-glycoprotein using physiologically based pharmacokinetic modeling

Wen Kou, Toshiaki Tsuchitani, Kazuya Maeda, Ryuto Tomabechi, Yuichi Sugiyama

Drug Metabolism and Disposition · 2026-07 · 54 (7) · 100333

DOI: 10.1016/j.dmd.2026.100333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-07. Verfasst von Wen Kou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, The First Hospital of Lanzhou University, Lanzhou, China; Innovation Base, Josai International University, Tokyo, Japan. Hauptthemen laut MEDLINE: Thiazoles, Quinidine, Pyridines, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science Society, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Edoxaban, a direct factor Xa inhibitor and known P-glycoprotein (P-gp) substrate, exhibits nonlinear increases in systemic exposure after oral administration and significant interaction with quinidine, a P-gp inhibitor. However, it remains unclear how P-gp in each organ contributes to these phenomena. We developed a physiologically based pharmacokinetic (PK) model to describe PK of edoxaban after oral (0.05-60 mg) and intravenous administration (30 mg), as well as its interaction with quinidine following edoxaban intravenously. Parameters were estimated using the Cluster Gauss-Newton method through top-down and middle-out approaches. Accurate description of renal clearance, which required incorporation of a hypothetical basolateral uptake process, underscoring the importance of unidentified renal transporters involved in edoxaban urinary secretion. Nonlinearity of dose-normalized area under blood concentration-time curve was highly sensitive to KmP-gp, with intestinal unbound concentrations exceeding KmP-gp at clinically relevant doses, consistent with intestinal P-gp saturation as the major driver of nonlinearity. In intravenous edoxaban-oral quinidine drug-drug interaction analysis, quinidine markedly reduced renal clearance and modestly increased hepatic availability, reflecting inhibition of renal and, to a lesser extent, hepatic P-gp. In conclusion, an edoxaban physiologically based PK model incorporating renal uptake transport enabled physiologically consistent description of renal clearance. Saturation of intestinal P-gp was identified as the primary contributor to nonlinear PK, while inhibition of renal P-gp was the main mechanism underlying the edoxaban intravenously administered with quinidine. These findings provide mechanistic insight into transporter contributions to edoxaban disposition and drug-drug interactions and highlight the importance of tissue-specific transporter processes in nonlinear pharmacokinetics. SIGNIFICANCE STATEMENT: Incorporating renal uptake transport is essential for mechanistically describing edoxaban renal clearance in physiologically based pharmacokinetic (PK) modeling. The model identifies intestinal P-glycoprotein saturation as the primary driver of nonlinear PK and renal P-glycoprotein inhibition as the major mechanism of the intraveous edoxaban-quinidine drug-drug interaction. These findings offer mechanistic insight into transporter contributions to edoxaban disposition and drug-drug interactions and emphasize the role of tissue-specific transport processes in nonlinear PK.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesQuinidinePyridinesATP Binding Cassette Transporter, Subfamily B, Member 1Models, BiologicalFactor Xa InhibitorsHumansDrug InteractionsAnimalsAdministration, OralMaleNonlinear DynamicsKidney

Stichwörter der Autor:innen

Cluster Gauss-Newton methodEdoxabanNonlinear pharmacokineticPhysiologically based pharmacokinetic model

Substanzen

ThiazolesQuinidinePyridinesedoxabanATP Binding Cassette Transporter, Subfamily B, Member 1Factor Xa Inhibitors

Autor:innen und Institutionen

  • Pharmacy Department, The First Hospital of Lanzhou University, Lanzhou, China; Innovation Base, Josai International University, Tokyo, Japan.
  • Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • School of pharmacy, Kitasato University, Tokyo, Japan.
  • Innovation Base, Josai International University, Tokyo, Japan; iHuman Institute, ShanghaiTech University, Shanghai, China. Electronic address: SugiyamaY@shanghaitech.edu.cn.

Förderung

  • Japan Science Society
  • National Natural Science Foundation of China

Zitieren

APA

Kou, W., Tsuchitani, T., Maeda, K., Tomabechi, R., & Sugiyama, Y. (2026). Mechanistic insights into edoxaban’s nonlinear pharmacokinetics and quinidine interaction via P-glycoprotein using physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition, 54(7), 100333. https://doi.org/10.1016/j.dmd.2026.100333

Vancouver

Kou W, Tsuchitani T, Maeda K, Tomabechi R, Sugiyama Y. Mechanistic insights into edoxaban’s nonlinear pharmacokinetics and quinidine interaction via P-glycoprotein using physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition. 2026;54(7):100333. doi:10.1016/j.dmd.2026.100333

BibTeX
@article{Kou2026,
  author = {Kou, Wen and Tsuchitani, Toshiaki and Maeda, Kazuya and Tomabechi, Ryuto and Sugiyama, Yuichi},
  title = {Mechanistic insights into edoxaban’s nonlinear pharmacokinetics and quinidine interaction via P-glycoprotein using physiologically based pharmacokinetic modeling},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {7},
  pages = {100333},
  doi = {10.1016/j.dmd.2026.100333}
}
Kostenlos starten →